Merus N.V. (NASDAQ:MRUS) COO Sells $924,275.00 in Stock

Merus N.V. (NASDAQ:MRUS - Get Free Report) COO Peter B. Silverman sold 16,805 shares of the firm's stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $55.00, for a total transaction of $924,275.00. The sale was disclosed in a document filed with the SEC, which is available through this link.

Peter B. Silverman also recently made the following trade(s):

• On Wednesday, July 9th, Peter B. Silverman sold 6,695 shares of Merus stock. The shares were sold at an average price of $55.00, for a total value of $368,225.00.
• On Friday, June 20th, Peter B. Silverman sold 34,000 shares of Merus stock. The stock was sold at an average price of $52.76, for a total value of $1,793,840.00.

Merus Price Performance

Shares of MRUS traded down $0.61 during trading hours on Friday, reaching $54.50. 315,839 shares of the company's stock traded hands, compared to its average volume of 738,704. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $62.98. The business's fifty day simple moving average is $50.55 and its two-hundred day simple moving average is $45.53. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of -13.36 and a beta of 1.00.

Merus (NASDAQ:MRUS - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative net margin of 506.73% and a negative return on equity of 35.99%. The company had revenue of $26.49 million during the quarter, compared to the consensus estimate of $7.82 million. On average, equities research analysts expect that Merus N.V. will post -3.85 EPS for the current year.

Institutional Investors Weigh In On Merus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in Merus during the 4th quarter valued at $347,000. GAMMA Investing LLC boosted its stake in Merus by 2,153.6% during the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock valued at $27,000 after buying an additional 603 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after buying an additional 300 shares in the last quarter. Northern Trust Corp grew its holdings in Merus by 61.2% during the fourth quarter. Northern Trust Corp now owns 76,335 shares of the biotechnology company's stock worth $3,210,000 after acquiring an additional 28,983 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in Merus in the fourth quarter worth about $817,000. Institutional investors own 96.14% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on MRUS shares. Guggenheim restated a "buy" rating and issued a $109.00 price target on shares of Merus in a research report on Friday, March 28th. BMO Capital Markets set a $110.00 target price on Merus and gave the company an "outperform" rating in a research note on Friday, May 23rd. Needham & Company LLC reiterated a "buy" rating and set a $75.00 price target on shares of Merus in a research report on Monday, May 19th. Wells Fargo & Company reduced their price objective on Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Finally, William Blair reaffirmed an "outperform" rating on shares of Merus in a research report on Monday, April 28th. Twelve equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Merus presently has a consensus rating of "Buy" and an average price target of $84.64.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.